Pharmaceuticals Add Strength to Lobbying

Posted April 22, 2013 at 7:44pm

Pharmaceutical companies and associations

have reported large increases in their lobby spending during the first quarter of 2013. Most have been lobbying in the areas of budget/appropriations; copyright/patents/trademarks; health; Medicare/Medicaid; and trade. For details on issues and specific bills see PhRMA’s report.

The Pharmaceutical Research & Manufacturers spent $5,270,000 – up from $4,940,000 in the last quarter of 2012.

Merck & Company spent $4,190,000 – up from $1,190,000.
Novartis Corporation spent $3,290,000 – up from 1,212,000.
Pfizer Inc. spent $2,870,000 – up from $1,730,000.
Eli Lilly & Company spent $2,610,000 – up from $2,055,000.
Sanofi-Aventis spent $1,800,000 – up from $1,590,000.
Teva Pharmaceuticals spent $1,570,000 – up from $750,000.
GlaxoSmithKline spent $1,510,000 – up from $1,370,000.
Johnson & Johsnon Inc. spent $1,430,000 – up from $880,000.
Amgen USA Inc. spent $2,290,000 – up from $2,250,000.
Bayer Corporation spent $1,820,000 – up from $1,150,000.
(more)
AstraZeneca Pharmaceuticals LP spent $1,210,000 – up from $340,000.
Genentech Inc. spent $1,202,000 – up  from $1,129,400.
Boehringer Ingelheim Pharmaceuticals Inc. spent $1,013,000 – up from $590,000.
EMD Serono Inc. spent $850,000 – up from $720,000.
Bristol-Myers Squibb Company spent $830,000 – down from $1,280,000
Abbott Laboratories spent $500,000 – down from $840,000.